MA-PSG
PSG, a leading growth equity firm partnering with lower middle-market software and technology-enabled service companies, today announced that it closed PSG Europe, the firm’s debut Europe-focused fund, with €1.25 billion in limited third-party partner commitments.
The fund, which was oversubscribed, received commitments from existing and new PSG investors, including state pension funds, sovereign wealth funds, family offices and high net worth individuals. The final close of PSG Europe brings PSG’s aggregate capital commitments across the U.S. and Europe to more than $5 billion.
The London-based PSG Europe team consists of 22 investment professionals advising on fund investments in European growth-stage and lower middle-market software and B2B services companies. PSG’s European investment strategy mirrors the firm’s buy and build strategy in the U.S., which has a track record of partnering with management teams to scale businesses through organic and inorganic growth.
“The final close of PSG Europe represents a significant milestone for PSG and firmly establishes our firm as one of Europe’s leading growth equity investors,” said Mark Hastings, Chief Executive Officer of PSG. “We’ve carefully built an exceptional investment team with deep industry expertise to capitalise on the opportunity we see across Europe.”
Peter Wilde, Chairman of PSG, added, “We are thrilled that our inaugural European fund has been met with such strong demand from a high-calibre and diversified group of limited partners. We are grateful for the support the fund has received from both new and returning investors, as it is a testament to the strength of the PSG platform and our investment approach.”
Dany Rammal, Managing Director and Head of the PSG Europe team, said, “The highly fragmented European market presents a significant opportunity for a firm like ours. The strength of our deal sourcing and operational capabilities mean we are well positioned to partner with founders and entrepreneurs to help them grow their businesses into leading pan-European software champions.”
To date, PSG Europe has made seven platform investments in Europe with the acquisitions of Hornetsecurity, Imaweb, MAPAL Group, Nomentia, Signaturit Solutions, SKEEPERS and Sympa, as well as 12 closed add-on acquisitions. Today, PSG’s European portfolio consists of companies with operations across 14 countries, enabling the acceleration of digital software solution adoption across large sectors of the economy.
Notes to Editors
PSG
PSG is a growth equity firm that partners with lower middle-market software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 65 companies and facilitated over 275 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG’s team operates out of offices in Boston, Kansas City and London. To learn more about PSG, visit www.psgequity.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005476/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Announces Commencement of Tender Offer for Shares of Waqoo, Inc.13.11.2025 09:57:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that on November 13, 2025, SBC Medical Group Co., Ltd. (the “Tender Offeror”) has resolved to acquire shares of common stock of Waqoo, Inc. (Securities Code: 4937, listed on the Tokyo Stock Exchange Growth Market; the “Target Company”) through a tender offer (the “Tender Offer”) pursuant to the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended; the “FIEA”), as described below. The Tender Offeror is a Japanese subsidiary ultimately owned by SBC Medical Group Holdings Incorporated (“SBCHD”), a U.S. corporation listed on NASDAQ and engaged in management support services for medical clinics both domestically and internationally. As of today, the Tender Offeror holds 353,600 shares of the Target Company’s common stock (ownership ratio: 9.49%).
IQM Launches Halocene, a New Quantum Computer Product Line for Error Correction13.11.2025 09:56:00 CET | Press release
IQM Halocene is a new quantum computer product line aimed at error correction development. It will start with a150-qubit system to be delivered by the end of 2026 and extend all the way to 1,000-qubits. The new product line is based on an open and modular error correction stack, which will allow end-users to experiment and run different quantum error correction features. IQM’s goal is to enable users from supercomputing centers, research organizations, and universities to innovate on quantum error correction research with an open platform. IQM has sold more on-premises quantum systems globally than any other manufacturer, and the company expects the new Halocene product line to accelerate its revenue growth further IQM Quantum Computers, a global leader in superconducting quantum computers, today announced the launch of its new product line called IQM Halocene. The new product line is based on open and modular on-premises quantum computers designed for quantum error correction research
JSR Life Sciences Enters Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings Limited13.11.2025 09:45:00 CET | Press release
Strategic Transaction Positions Crown Bioscience for Accelerated Growth in Translational Oncology JSR Life Sciences LLC ("JSR Life Sciences"), a global leader in life sciences materials and services, today announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. ("Crown Bioscience") to Adicon Holdings Limited ("Adicon"), a premier independent clinical laboratory provider in China and a portfolio company of The Carlyle Group. The transaction, subject to customary closing conditions, is expected to close in 2026. This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership. Crown Bioscience's comprehensive portfolio of translational oncology services, including its world-leading patient-derived xenograft (PDX) models, tumor organoid platforms, immuno-oncology assays, and bioinformatics solutions, will transition to Adicon, positioning the company to accelerate advancements in precision medicine and drug discover
Ohmium Breaks Barriers: Exceeds 2030 Industry Targets of 10 GW/ton to Achieve 18 GW/ton Iridium Utilization13.11.2025 09:05:00 CET | Press release
Ohmium International Inc., a leading provider of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has surpassed the PEM electrolyzer industry's 2030 target of 10 GW per ton to attain an 18 GW per ton iridium utilization rate. Ohmium has made significant technological advancements which have resulted in reducing its iridium usage by 50% in its Lotus electrolyzer, Mark 2. This enhances the cost-competitiveness of green hydrogen production by reducing the overall cost of its PEM electrolyzers, which have been impacted by the cost of the precious metal, iridium. Dr. Chock Karuppaiah, Ohmium Chief Science and Technology Officer, said, "We've made significant strides in reducing iridium usage in our PEM electrolyzers, exceeding the 2030 industry target of 10 GW per ton. We've achieved a utilization rate of 18 GW per ton. This innovation is crucial, as iridium is one of the most expensive materials in electrolyzer manufacturing.” Dr. Markus Tacke, Ohmiu
Europe Must Embrace Long Duration Energy Storage to Manage Costs and Meet Climate Goals: New Report13.11.2025 09:01:00 CET | Press release
Providing greater revenue certainty for long duration energy storage will save grid operating and curtailment costs, avoid stranded assets, and enable energy independence Policies to incentivize investment in longer duration energy storage can mitigate billions in grid costs, while helping the continent hit its 2050 climate goals and achieve energy independence, according to a new whitepaper from Hydrostor. The paper explores how, through policies aimed at increasing strategic investment in long duration energy storage (LDES), EU member states could cut grid expansion and curtailment costs by 2040, while avoiding spending billions on stranded natural gas assets1. Deploying these technologies across Europe can save €103 billion by 2040, according to recent research from Energy Storage Europe Association. Doing so in the UK could save €35 billion by 2050, according to LCP Delta analysis on behalf of the UK government.2 Hydrostor President, Jon Norman, said: “As global momentum grows behi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom